ロード中...
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
BACKGROUND: RECORD-3 assessed non-inferiority of progression-free survival (PFS) with everolimus vs sunitinib in previously untreated patients with metastatic renal cell carcinoma. Baseline plasma sample collection and randomised design enabled correlation of circulating biomarkers with efficacy. ME...
保存先:
| 出版年: | Br J Cancer |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4800293/ https://ncbi.nlm.nih.gov/pubmed/26908330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.21 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|